PMcardio receives FDA Breakthrough Device Designation — read the full story
Powerful Medical
11. November 2024
3 min to read

AI-Enhanced Recognition of Occlusion in Acute Coronary Syndrome (AERO-ACS): A Retrospective Review

Overview

Conventional ECG criteria often fail to detect severe coronary blockages, leading to delayed treatment and worse outcomes. The team at Mt. Sinai Morningside performed a retrospective validation of the PMcardio STEMI AI ECG Model, demonstrating 81% sensitivity and 87% specificity in identifying high-risk patients. The AI model nearly doubled the sensitivity of STEMI criteria and correctly reclassified false positives, potentially reducing unnecessary catheterizations while ensuring no true heart attacks were missed.

Published In: Circulation (AHA Journals) – presented at the American Heart Association (AHA) 2024 Scientific Sessions
Presented Date: November 11, 2024

Background

Traditional ST-elevation criteria do not exhibit high sensitivity for acute occlusion detection, with many total occlusions presenting as NSTEMI, often resulting in worse outcomes. AI-based EKG interpretation may improve the identification of occlusion myocardial infarction (OMI). This study evaluates a novel AI-EKG device’s accuracy and clinical outcomes for detecting OMI in suspected ACS patients.

Methods

Adult patients who underwent coronary angiogram (CAG) at Mount Sinai Morningside Hospital for unstable angina, NSTEMI, or STEMI between January 1 and December 31, 2022, were included. The AI model (PMCardio) analyzed all pre-CAG ECGs. Inclusion criteria: suspected ACS at the emergency department, no outside hospital transfers, and available peak troponin levels. OMI was defined as a culprit vessel with TIMI 0-2 flow or TIMI 3 flow and peak cTnI > 10.0 ng/mL.

Primary outcome: AI EKG model’s sensitivity and specificity for predicting OMI on CAG. Secondary outcomes: F1 score, predictive values, AI OMI prediction of inpatient mortality, reduced ejection fraction at 1 year, unplanned readmissions, and STEMI criteria performance.

Results

Of 257 patients, 222 met the inclusion criteria: 72 STEMI (32%), 145 NSTEMI (65%), and 5 unstable angina (3%). Confirmed angiographic OMI: 60 (83%) STEMI and 51 (35%) NSTEMI patients. AI model sensitivity was 81.08%, specificity 87.39%, AUROC 0.8423, F1 score 0.8372, PPV 86.54%, NPV 82.20%. Odds ratio of 12.44 (1.56 – 98.98) for AI-detected OMI patients, unplanned readmissions (OR 1.15 [0.53 – 2.51]), and reduced ejection fraction at 1 year (OR 0.24 [0.26 -2 .16]).

Traditional STEMI criteria sensitivity for OMI was 54.05%, and specificity 89.29%. The AI model was 100% sensitive for STEMI-OMI and correctly reclassified 8 out of 12 false positive STEMI patients as NOMI.

Conclusion

The AI model nearly doubles the sensitivity of traditional STEMI criteria for OMI, enabling more accurate and earlier detection. Further studies are needed to determine if earlier OMI detection with AI improves clinical outcomes. The AI’s high specificity in detecting STEMI-OMI may also reduce false positive catheterization lab activations while ensuring no true positive STEMI OMI cases are missed.

Authors: James Choi, MBBS, Vincent Torelli, DO, Sara Diaz, MD, Esha Vaish, MBBS, Luka Katic, MD, Alex Nagourney, MD, Zara Khan, DO, Alex Silverman, MD, Serdar Farhan, MD

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Validation of an artificial intelligence ECG model for detection of acute coronary occlusion myocardial infarction in unselected emergency department chest pain patients

Across 24 513 consecutive chest-pain presentations to five Swedish emergency departments, the Queen of Hearts (QoH) AI-ECG model detected acute coronary occlusion myocardial infarction with 52 % sensitivity and 99 % specificity. It outperformed an extended STEMI algorithm applied to the same cohort (41 % sensitivity, 95 % specificity) and more than doubled the sensitivity of classic STEMI criteria (55 % versus 26 %) while preserving comparable specificity (99 % versus 98 %). This real-world validation demonstrates that QoH markedly improves early ECG recognition of OMI in unselected, non-traumatic chest-pain patients.

Artificial Intelligence Based Detection of Acute Coronary Occlusion Compared to STEMI Criteria – External Validation Study in a Consecutive All-Comer German Chest Pain Unit Cohort

2nd place - DGK Young Investigator Awards 2025, Germany: In a real-world cohort of over 4,000 chest pain patients presenting to a German CPU, excluding obvious STEMI heart attacks diagnosed before arrival, an AI ECG model detected serious artery blockages (ACO) with 97.8% accuracy. It outperformed traditional STEMI criteria, achieving higher sensitivity (70.2% vs 28.8%) and fewer false positives.

Join over 100,000 healthcare professionals who are already taking advantage of AI